Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Active:	No
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04142619
Trial Phases:	Phase I	Protocol IDs:	UCARTCS1A_01 (primary) NCI-2019-07562
Eligibility:	18 - 64 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Cellectis S.A.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04142619

Summary

This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy
of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The
purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to
determine the Maximum Tolerated Dose (MTD).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.